Quest Diagnostics reported a stronger second quarter of 2026, while also detailing several recent corporate actions: a new long-term debt issuance and repayment of maturing notes, completion of a Michigan laboratory venture with Corewell Health, and ongoing restructuring under its Invigorate productivity program. For the quarter ended June 30, 2026, Quest Diagnostics generated net revenues of $3.043 billion, up 10.2% from $2.761 billion a year earlier. Its core Diagnostic Information Services business, which accounts for more than 95% of consolidated revenue, produced $2.978 billion in revenue, up 10.3% from $2.699 billion in the prior-year quarter. Diagnostic Solutions revenue was $65 million, compared with $62 million a year earlier. Operating income rose to $459 million from $438 million, while net income attributable to Quest Diagnostics increased to $320 million from $282 million. Diluted earnings per share were $2.84, compared with $2.47 in the second quarter of 2025. The company said Diagnostic Information Services volume increased 13.1% year over year in the second quarter, with organic requisition volume up 13.0%. Approximately 9 percentage points of that growth came from Quest’s new relationship with Corewell Health and expanded laboratory testing at U.S. dialysis clinics owned by Fresenius Medical Care. Excluding those two relationships, organic volume increased about 4%. Revenue per requisition declined 2.8%, primarily because the Corewell Health and Fresenius Medical Care work carries a higher proportion of routine testing; excluding those mix effects, revenue per requisition increased approximately 3%, helped by a higher number of tests per requisition. A key financing action occurred in May 2026, when Quest completed a senior notes offering of $500 million aggregate principal amount of 5.00% senior notes due June 2036. The notes were issued at an original issue discount of $6 million. On June 1, 2026, Quest used the net proceeds from that offering, together with cash on hand, to repay in full at maturity its outstanding $500 million of 3.45% senior notes. The transaction effectively refinanced a maturing debt obligation with longer-dated 2036 notes, extending the company’s debt maturity profile while locking in a higher coupon. Quest also reported that its previously announced venture with Corewell Health was completed in January 2026. The companies had signed a definitive agreement in August 2025 to form a new entity that will perform laboratory testing in Michigan through a new laboratory facility. Corewell Health contributed a laboratory business, and Quest obtained a controlling financial interest. Ownership of the new entity is split 51% Quest Diagnostics and 49% Corewell Health, and Quest is consolidating the venture in its financial statements. Until the new laboratory is operational in 2027, the parties are continuing to serve Michigan providers and patients through existing patient service centers and laboratories, with the patient service centers operated by the newly formed entity. The company also continued its multi-year Invigorate program, which is designed to drive annual cost savings and productivity improvements of about 3% across areas such as patient services, logistics, laboratory operations, revenue services, information technology and procurement. For the six months ended June 30, 2026, Quest recorded $11 million of pre-tax restructuring and integration charges, including $9 million of employee separation costs, with the remainder largely tied to integration activities. In the second quarter alone, these charges totaled $4 million, recorded as $1 million in cost of services and $3 million in selling, general and administrative expenses. Quest said most of the charges will result in cash expenditures and that additional restructuring and integration charges may be incurred in future periods. For the first six months of 2026, Quest reported net revenues of $5.938 billion, up 9.7% from $5.413 billion in the first half of 2025. Diagnostic Information Services revenue increased 9.9% to $5.810 billion, while Diagnostic Solutions revenue rose 2.5% to $128 million. Operating income increased 9.4% to $858 million from $784 million, and net income attributable to Quest Diagnostics rose 13.9% to $572 million from $502 million. Diluted earnings per share for the six-month period were $5.08, compared with $4.41 a year earlier. Quest noted several items affecting earnings. In the second quarter of 2026, reported diluted EPS was reduced by a net $0.28, including $38 million of pre-tax amortization expense, or $0.25 per diluted share; $4 million of restructuring and integration charges, or $0.04 per diluted share; and $1 million of charges mainly tied to fair-value changes in contingent consideration from prior acquisitions, or $0.02 per diluted share. These were partly offset by $1 million of gains related to strategic investments and $2 million of excess tax benefits from stock-based compensation. For the first half of 2026, similar items reduced diluted EPS by a net $0.54. This Form 10-Q does not report an insider stock purchase or sale and does not include transaction codes associated with insider trading forms. Instead, it provides Quest Diagnostics’ quarterly financial results and updates on corporate financing, business formation, restructuring and operating performance for the quarter ended June 30, 2026.